Health Care [ 11/12 ] | Biotechnology [ 66/75 ]
NASDAQ | Common Stock
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.
Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
It has license agreement with Orchard Therapeutics Limited.
The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.36 Decreased by -271.43% | -0.40 Increased by +10.00% |
| Mar 26, 24 | -0.70 Increased by +13.15% | - |
| Nov 7, 23 | -0.66 Increased by +29.79% | -0.67 Increased by +1.49% |
| Aug 8, 23 | -0.67 Increased by +47.24% | -0.72 Increased by +6.94% |
| May 9, 23 | 0.21 Increased by +112.65% | -0.37 Increased by +156.76% |
| Mar 29, 23 | -0.81 Increased by +62.15% | -0.44 Decreased by -84.09% |
| Nov 7, 22 | -0.94 Increased by +70.25% | -1.12 Increased by +16.07% |
| Aug 4, 22 | -1.27 Increased by +62.97% | -1.24 Decreased by -2.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 18.57 M Increased by +169.56% | -69.80 M Increased by +4.26% | Decreased by -375.84% Increased by +64.48% |
| Mar 31, 24 | 18.57 M Increased by +680.05% | -69.80 M Decreased by -305.05% | Decreased by -375.84% Decreased by -126.29% |
| Dec 31, 23 | 7.83 M Increased by +12.54 K% | -88.51 M Decreased by -374.62% | Decreased by -1.13 K% Decreased by -102.17% |
| Sep 30, 23 | 12.39 M Increased by +17.35 K% | -71.73 M Increased by +6.26% | Decreased by -578.85% Increased by +99.46% |
| Jun 30, 23 | 6.89 M Increased by +353.59% | -72.91 M Increased by +21.50% | Decreased by -1.06 K% Increased by +82.69% |
| Mar 31, 23 | 2.38 M Increased by +22.42% | 34.04 M Increased by +127.46% | Increased by +1.43 K% Increased by +122.43% |
| Dec 31, 22 | 62.00 K Decreased by -96.14% | 32.23 M Increased by +120.79% | Increased by +51.99 K% Increased by +638.47% |
| Sep 30, 22 | 71.00 K Decreased by -99.69% | -76.52 M Increased by +64.71% | Decreased by -107.77 K% Decreased by -11.17 K% |